Severity Assessment and Treatment for Acute Pancreatitis in Japan
Yoshifumi Takeyama,Morihisa Hirota,Tooru Shimosegawa,Atsushi Masamune,Shin Hamada,Kazuhiro Kikuta,Ichiro Tsuji
2016-01-01
Pancreas
Abstract:Proceedings of the Japan Pancreas Society, 2015, Suizo, the Journal of the Japan Pancreas Society, Volume 30, 2015, Yoshifumi Takeyama, MD, PhD, Editor-in-Chief JPS SELECTED ABSTRACT 1 Severity Assessment and Treatment for Acute Pancreatitis in Japan Morihisa Hirota,* Tooru Shimosegawa,* Atsushi Masamune,* Shin Hamada,* Kazuhiro Kikuta,* Ichiro Tsuji. *Division of Gastroenterology; †Division of Epidemiology, Department of Public Health and Forensic Medicine; Tohoku University Graduate School of Medicine, Miyagi, Japan. Suizo. Vol 30, No 1, pp 123–136. Aim: The aim of this study was to clarify the severity assessment and treatment strategy for patients with acute pancreatitis (AP) in Japanese hospitals. Methods: A nationwide survey was conducted targeting patients with AP who were treated in Japanese hospitals in 2011. Clinical data of 2,694 patients were accumulated and analyzed. Results: There are two independent scoring systems for severity assessment of AP in Japan; one is a prognostic score and the other is a contrast-enhanced CT grade (CECTgrade). It is recommended that the severity assessment bemade immediately after the diagnosis and repeated over time (especially within 48 hour of the diagnosis). The severity of patients with AP, which was estimated by the Japanese severity scoring system on admission, was well correlated with the in-hospital mortality (Fig. 1). The utility of the following treatments were addressed; early fluid therapy, early enteral nutrition therapy, early use of antibiotics and protease inhibitors, continuous regional arterial infusion (CRAI) of protease inhibitor and antibiotics therapy and blood purification therapy. Currently, 14.7% of patients in Japan with severe AP underwent CRAI of protease inhibitor. Moreover, the utility of endoscopic treatment for acute gallstone pancreatitis and walled-off necrosis (WON) were also addressed. Conclusion: Early severity assessment according to the Japanese severity scoring systemwas useful. Prospective studies are necessary to estimate the efficacy of each therapy, such as CRAI of protease inhibitor, which is currently performed in some Japanese hospitals. FIGURE 1. Severity assessment on admission correlates with in-hospital mortality. 83.6% of patients underwent CE CT on admission and 82.8% of them underwent CE CT within 48 hours of onset. ND, no data. Pancreas • Volume 45, Number 6, July 2016 Copyright © 2016 Wolters Kluwer REFERENCES: 1. Hamada S, Masamune A, Kikuta K, et al. Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas. 2014;43:1244–1248. 2. Yokoe M, Takada T, Mayumi T, et al. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Sci. 2015;22:405–432. 3. Takeda K, Matsuno S, Sunamura M, et al. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996; 17:394–398. JPS SELECTED ABSTRACT 2 Pancreatic Carcinoma In Situ, Presenting as Prominent Fatty Changes in the Pancreatic Body on Computed Tomography: Experience of 3 Cases Masataka Kikuyama,* Keiji Hanada,† Toshiharu Ueki.‡ *Department of Gastroenterology, Shizuoka General Hospital, Shizuoka, Shizuoka, †Department of Gastroenterology, JA Onomichi General Hospital, Onomichi, Hiroshima, ‡Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushi, Fukuoka, Japan. Suizo. Vol 30, No 4, pp 626–632. We noticed a high degree of fatty changes in the pancreatic parenchyma of the pancreatic body in 3 of 14 patients with pancreatic carcinoma in situ. The fatty changes were observed along the lesions of pancreatic carcinoma in situ on histopathological examination. In 1 patient, the cancerous lesion had spread widely along the dilated branch andmain pancreatic duct of the pancreatic body, and abdominal contrast enhanced computed tomography (CE-CT) showedwide fatty change replacing the pancreatic parenchyma around the dilated pancreatic ducts (Figure 1A). In the other 2 patients, the cancerous lesions were recognized in the branch of the pancreatic duct of the pancreatic body, and fatty changes of the pancreatic body were visualized locally on CE-CT (Figure 1B, 1C). The size of the fatty change depended on the width of the carcinoma in situ. Interactions between the pancreatic carcinoma in situ and fatty changes of the pancreatic parenchyma are unclear. We speculate that peroxisome proliferator-activated receptor γ (PPARγ) activation is the key to these phenomena. Pancreatic cancer involves abundant fibrosis in the tissue that can contribute to the progression of pancreatic cancer. Transforming growth factor β (TGFβ) is responsible for the fibrosis. Activation of PPARγ suppresses TGFβ activity and leads to advancement of pancreatic cancer and inhibition of tumor progression and metastasis by inhibiting epithelial-mesenchymal transitions. We believe that PPARγ activation prevents the progression of carcinoma in situ to advanced pancreatic cancer and induces adipogenesis of pancreatic stellate cells and fatty changes around the carcinoma in situ. REFERENCES: 1. Bachem MG, Schünemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128:907–921. 2. Toyota M, Miyazaki Y, Kitamura S, et al. Peroxisome proliferatoractivated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci. 2002;70:1565–1575. 3. Lee SJ, Yang EK, Kim SG. Peroxisome proliferator-activated receptorγ and retinoic acid X receptor α represses the TGFβ1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosporylation. Mol Pharmacol. 2006;70;415–425. 4. Reka AK, Kurapati H, Narala VR, et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition.Mol Cancer Ther. 2010;9:3221–3232. 5. Kruse ML, Hopf-Jensen S, Timke C, et al. Differentiation potential of pancreatic fibroblastoid cells/stellate cells: effects of peroxisome proliferatoractivated receptor gamma ligands. Int J Cell Biol. 2011;2011:816791. www.pancreasjournal.com 919 Health, Inc. All rights reserved. FIGURE 1. Abdominal contrast enhanced computed tomography (CE–CT). A,CE–CT shows wide fatty change replacing the pancreatic parenchyma around the dilated pancreatic duct of the pancreatic body (arrow). B, Fatty changes along the main pancreatic duct of the pancreatic body are visible (arrow). C, Local fatty changes are seen in the pancreatic body (arrow). Abstracts Pancreas • Volume 45, Number 6, July 2016 JPS SELECTED ABSTRACT 3 Strategy of Symptom-Targeted Intervention Based on Patient Quality of Life at Three Months After Pancreatectomy Naoko Sato,* Yu Katayose,†§ Fuyuhiko Motoi,‡§ Kei Nakagawa,†§ Naoaki Sakata,§ Kei Kawaguchi,§ Fumiko Sato,* Michiaki Unno.†‡ Departments of *Oncology Nursing; †Integrated Surgery and Oncology; ‡Hepato-Biliary Pancreatic Surgery; Tohoku University Graduate School of Medicine, Miyagi, Japan; §Hepato-Biliary Pancreatic Surgery, Tohoku University Hospital, Miyagi, Japan. Suizo. Vol 30, No 5, pp 654–662. Background: Surgical resection is the only treatment expected to cure pancreatic cancer but is very invasive. It usually causes severe stress in patients and may cause pain and deterioration of quality of life (QOL). Data that patients provide about their QOL are essential for describing patient symptomatology and evaluating care in order to adequately manage symptoms of the disease. FIGURE 1. Comparison of QOL before and after SSPPD and DP. QOL w and 3 months after surgery in the SSPPD (n = 16) and DP (n = 15) grou and VT, whereas the DP group showed no significant change in QOL. Q pancreatoduodenectomy; DP, distal pancreatectomy; PF, physical funct health; SF, social functioning; BP, bodily pain; VT, vitality; MH, mental h 920 www.pancreasjournal.com Copyright © 2016 Wolters Kluwer H Aim: To determine the level of health-relatedQOL (HRQOL) and symptoms of pancreatic cancer patients 3 months after surgical intervention. Materials and Methods: We statistically evaluated the correlation between the Short Form 36 Health Survey version 2 (SF-36v2 Standard, Japanese), which measures HRQOL, and specific symptoms of hepatobiliary and pancreatic cancer using data acquired from 33 postoperative pancreatic cancer patients: subtotal stomach-preserving pancreatoduodenectomy (SSPPD), 16 patients; distal pancreatectomy (DP), 15 patients; total pancreatectomy (TP), 1 patient; bypass surgery, 1 patient. Results:Deterioration ofQOLwas observed inmany parameters of SF-36v2 at 3 months postoperatively. In particular, physical functioning (PF) (p <0.001), role physical (RP) (p <0.01), vitality (VT) (p <0.05) and role emotional (RE) (p <0.05) were significantly reduced in the SSPPD patients. (Fig. 1) Our data also revealed that appetite loss (PF, RP, general health (GH), VT, RE, mental health (MH) (p <0.01-0.05)), discomfort or pain in the stomach area (RP, BP, GH, VT, SF, MH (p <0.01-0.05)), and general fatigue and discontent with as compared on eight domains of the SF-36v2 between before ps. The SSPPD group showed significant decreases in PF, RP OL, quality of life; SSPPD, subtotal stomach-preserving ioning; RP, role physical; RE, role emotional; GH, general ealth. © 2016 Wolters Kluwer Health, Inc. All rights reserved. ealth, Inc. All rights reserved. Pancreas • Volume 45, Number 6, July 2016 Abstracts change in appearance (PF, RP, GH, VT, SF, RE, MH (p <0.01)) correlated with QOL deterioration. (Fig. 1) Conclusion: QOL can be improved by a combination of treatments for symptoms related to digestion and absorption,management of nutrition and treatment for subjective symptoms including fatigue. REFERENCES: 1. Labori KJ, Hjermstad MJ, Wester T, et al. Symptom profiles and palliative care in advanced pancreatic cancer: a prospective s